BRAD NEWLAND BOLON
Office
GEMpath, Inc. Phone: (435) 867-4734
2540 N. 400 W. E-Mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Cedar City, UT 84720-8400
EDUCATION
Ph.D. in Pathology
1993, Duke University, Department of Pathology, Durham, NC. Research dissertation in neurotoxicologic pathology, entitled "Methanol-induced neural tube defects: Characterization of lesions, target and teratogen."
Postdoctoral Trainee in Pathology
1989-1993, Chemical Industry Institute of Toxicology (CIIT), Department of Experimental Pathology and Toxicology, Research Triangle Park, NC. Basic mechanistic research in mechanisms of developmental neurotoxicity.
General Graduate Studies
1988-1989, University of Florida, Department of Comparative and Experimental Pathology, Gainesville, FL. Training in the theory and practice of biomedical research.
Residency in Veterinary Pathology
1986-1988, University of Florida, Department of Comparative and Experimental Pathology, Gainesville, FL. Training in comparative anatomic pathology.
D.V.M. in Veterinary Medicine
1986, University of Missouri, Columbia, MO. Training in diagnosis and therapy of animal diseases for domestic, laboratory, and exotic species.
M.S. in Veterinary Physiology and Pharmacology
1986, University of Missouri, Department of Veterinary Biomedical Sciences, Columbia, MO. Research thesis in behavioral neurotoxicology, entitled "The neurotoxic effects of secalonic acid D in suckling mice following postnatal exposure via the dams' milk."
B.S. with Honors in General Agriculture
1983, University of Missouri, Columbia, MO.
Continuing Education – Short Courses and Focused Symposia
1988 The Nervous System of Laboratory Animals; October 30 - November 1.
International Life Sciences Institute (ILSI), Kansas City, MO.
1989 Diagnosis and Treatment of Diseases of Warm Water Fish; June.
University of Florida, Gainesville, FL. June.
1990 Gross Morbid Anatomy of Animals; March 28-30.
Armed Forces Institute of Pathology (AFIP), Bethesda, MD.
1990 Aquavet II: Histopathology of Aquatic Animals; May 13-26.
Marine Biological Laboratory, Woods Hole, MA.
1990 Pathology of Laboratory Animals; August 13-17.
Armed Forces Institute of Pathology (AFIP), Bethesda, MD.
1990 Physiologically-Based Pharmacokinetic (PBPK) Models: Principles and
Implementation; November 13-15. Chemical Industry Institute of
Toxicology (CIIT), Research Triangle Park, NC.
1990 The Hemopoietic System of Laboratory Animals; December 8-10.
International Life Sciences Institute (ILSI), Phoenix, AZ.
1991 Computer-Assisted Image Analysis and Measurement; May 13-15.
North Carolina State University, Raleigh, NC.
1993 Recombinant DNA Techniques I; September 14-18.
Recombinant DNA Techniques II; September 21-26.
Life Technologies, Inc., Germantown, MD.
1994 The Endocrine System of Laboratory Animals; October 29-31.
International Life Sciences Institute (ILSI), Montreal, Canada.
1995 In Situ Hybridization; June 26-30.
Center for Advanced Training in Cell and Molecular Biology (CAT-CMB),
Catholic University of America, Washington, D.C.
1996 Molecular Diagnostics and Experimental Pathology - Methods,
Applications, and Animal Models; June 23-27.
C.L. Davis Foundation 20th Annual Continuing Education Symposium,
Baylor University Medical Center, Houston, TX.
1997 The Nervous System of Laboratory Animals; September 3-5.
International Life Sciences Institute (ILSI), Hannover, Germany.
[Faculty Member]
1998 Toxicologic Pathology of Biotechnology Products; June 28 - July 3.
Society of Toxicologic Pathologists (SOTP) 17th International Symposium, Vancouver, British Columbia, Canada.
1999 Toxicologic Pathology of the Nervous System; June 13-17.
Society of Toxicologic Pathologists (SOTP) 18th International Symposium, Washington, D.C. [Faculty Member]
2002 Pathobiology of the Laboratory Mouse; June 23-29 (inaugural course).
The Jackson Laboratory, Bar Harbor, MN.
2003 2nd Annual Short Course, Pathobiology of the Laboratory Mouse; July 6-13.
The Jackson Laboratory, Bar Harbor, MN. [Faculty Member]
2004 Pathology of the Nervous System; September 12-14.
2nd RTP Rodent Pathology Course, National Institute of Environmental Health Sciences (NIEHS), Research Triangle Park, NC. [Faculty Member]
2005 2nd European Short Course on Pathology and Embryology of Genetically
Engineered Mice (EuroGEMs); May 9-13
Veterinary School of Nantes, France. [Faculty Member]
2005 Comparative Physiology for Toxicologists; November 14-15
U.S. Food and Drug Administration, Silver Spring, MD. [Faculty Member]
2005 Seminars on Advanced Pathologic Techniques: Current Issues in Neuropathology; December 2.
International Life Sciences Institute (ILSI) Health and Environmental Sciences Institute (HESI), Boston, MA (as a satellite meeting to ACVP)
[Faculty Member and Co-Chair]
PROFESSIONAL LICENSURE AND CERTIFICATION
Practitioner — Missouri Veterinary Medical Board, 1986
Diplomate — American College of Veterinary Pathologists, 1991
Diplomate — American Board of Toxicology, 1996 (re-certified 2001 and 2006)
Fellow — International Academy of Toxicologic Pathology, 2007
PROFESSIONAL WORK EXPERIENCE
GEMpath, Inc., Cedar City, UT - March, 2004 to present.
Founder. Basic bio/pharmaceutical research, emphasizing morphologic analysis of genetically engineered (especially developing) mice, target validation, and efficacy and safety studies (rats, rabbits, dogs, primates) for proteins and small molecules.
Amgen, Inc., Thousand Oaks, CA - August, 1997 to February, 2004.
Experimental Pathologist in the Department of Pathology. Basic and applied drug discovery research using morphological techniques to characterize novel molecular targets and the effects of recombinant proteins and small molecules in engineered mouse models (transgenic, knock-out, viral gene therapy vectors) of human genetic diseases. Principal pathologist responsible for analyzing embryos and fetuses from genetically engineered mouse lines. Operations manager of the clinical pathology laboratory (1998 to present) with supervisory responsibility for two technologists. Supervisor (1998 to 2002) of an efficacy bioassay for sustained release formulations of recombinant proteins, with oversight of one biologist. Primary or peer review pathologist (occasional basis) for rodent exploratory toxicity bioassays. Member of preclinical development teams for anakinra (Kineret®), pegsunercept, and three other lead compounds in discovery research. Member of the Amgen Disaster Response Team.
Wyeth-Ayerst Research, Princeton, NJ - May, 1996 to July, 1997.
Senior Research Scientist II - Molecular Biology, Division of Molecular Genetics. Morphologic characterization of genetically engineered animal models for human cardiovascular, endocrine, metabolic, and neural diseases using in situ molecular assays (enzyme and immunohistochemistries, nucleic acid hybridization). Leader in designing and managing core services for microscopy, photomicrography, and digital imaging with supervisory responsibility for one worker. Ancillary duties as an occasional pathologist for the animal facility (rodents, dogs, primates), as a member of the Discovery Research Executive Staff for strategic planning, and as an advisor for the Transgenic Animal Barrier Oversight Committee.
Pathology Associates International (PAI) - August, 1993 to March, 1996.
1. Operations Manager and Staff Pathologist - November, 1994 to March, 1996.
Contract scientist at the U.S. Food and Drug Administration's National Center for Toxicological Research (NCTR; Jefferson, AR). Applied research in the toxicologic pathology of food-borne chemicals and medical devices, chiefly histopathological analysis of tissues from acute and chronic rodent bioassays. Mechanistic research (working with FDA scientists) in the impact of caloric restriction on morphological endpoints, in the carcinogenicity of silicone implants, and in the developmental toxicity of teratogenic acids. Operations manager of clinical pathology, electron microscopy, and image analysis services with supervisory responsibility for nine workers. Principal pathologist for regulatory toxicology studies (performed with rodents, dogs, and primates) at a commercial toxicology laboratory.
2 Associate Director and Senior Pathologist - August, 1993 to November, 1994.
Applied scientist in the Molecular and Immunopathology Division (Frederick, MD). Project manager for human tissue cross reactivity studies to support development of novel monoclonal antibody reagents and for safety assessment bioassays of federal and private-sector clients (performed with rodents, rabbits, and dogs). Applied contract research in the use of immunohistochemical methods to augment histopathological criteria of conventional regulatory toxicity studies. Consulting pathologist with discovery groups of three biotechnology firms regarding unusual toxicities associated with administration of fusion proteins and oligonucleotides.
Consultant (Self-Employed) - July, 1989 to May, 1995.
Intermittent service work in diagnostic pathology of toxic and infectious diseases in freshwater tropical fishes.
Chemical Industry Institute of Toxicology (CIIT), Research Triangle Park, NC - July, 1989 to August, 1993.
Postdoctoral Trainee, Department of Experimental Pathology and Toxicology. Applied research to elucidate mechanisms of developmental neurotoxicity using in vivo (mouse bioassay) and in vitro (mouse whole embryo culture, primary neural cell culture) models. Cross-training in chemical carcinogenesis assays (in vivo and in vitro) and physiologically-based risk assessment.
University of Florida, Gainesville, FL - July, 1986 to June, 1989.
1. Graduate Research Associate - July, 1988 to June, 1989.
Department of Comparative and Experimental Pathology, College of Veterinary Medicine. Basic and applied research in flow cytometric and immunohistochemical tumor diagnostic techniques as well as instruction of veterinary pathology residents and senior veterinary students in comparative anatomic pathology.
2. Resident and Visiting Instructor -July, 1986 to June, 1988.
Department of Comparative and Experimental Pathology, College of Veterinary Medicine. Lecture and laboratory instruction of sophomore and senior veterinary students in comparative anatomic pathology.
University of Missouri, Columbia, MO - August to December, 1995.
Graduate Teaching Assistant, Department of Veterinary Biomedical Sciences, College of Veterinary Medicine. Laboratory instructor in comparative anatomy.
TEACHING EXPERIENCE
Adjunct Faculty, Veterinary Biomedical Sciences
2006 to present, University of Missouri, Columbia, MO; College of Veterinary Medicine. Deliver periodic lectures on pathology of genetically engineered mice for faculty, residents, and students.
Guest Lecturer, Pathology
2001, Washington State University, Pullman, WA; School of Veterinary Medicine. Gave a series of talks on pathology of genetically engineered mice, developmental pathology, and pathology opportunities in pharmaceutical research to pre-veterinary and veterinary students, pathology residents, and faculty.
Mentor, Necropsy and Clinical Pathology
1998 to 2004, Amgen, Thousand Oaks, CA. Taught individuals in the Laboratory Animal Resources department basic concepts of gross and histopathology, clinical chemistry and hematology (discussion and lab). Mentored research associates in the Pathology and Toxicology departments concerning basic methods in successful technical writing.
Guest Lecturer, Toxicology
1996, University of Arkansas-Medical Sciences (UAMS), Little Rock, AR; Integrated Toxicology Program. Gave a 2-hr lecture entitled "Nomenclature of Neoplasms and Preneoplastic Lesions" to first-year graduate students.
Mentor, Necropsy and Clinical Pathology
1995 to 1996, Pathology Associates International (PAI), at the U.S. Food and Drug Administration's National Center for Toxicological Research (NCTR), Jefferson, AR. Trained rodent necropsy technicians to perform canine and primate necropsies. Initiated and supervised short courses in (1) basic clinical chemistry and hematology for high school graduates (lecture and lab) and (2) safety practices for handling biohazardous materials (lecture only).
Lecturer, Basic Pathology
1990, Chemical Industry Institute of Toxicology (CIIT), Research Triangle Park, NC. Served as co-director for a one-week short course entitled "Basic Pathology for the Biomedical Scientist." Gave a 2-hr lecture entitled "Mechanisms and Morphology of Inflammatory Diseases.
Visiting Instructor
1986-1988, University of Florida, Department of Comparative and Experimental Pathology. Lecture (four 1-hr sessions) and laboratory instruction (biweekly for four semesters) of sophomore and senior veterinary students in comparative anatomic pathology.
Graduate Teaching Assistant
1985, University of Missouri, Department of Veterinary Biomedical Sciences. Laboratory instructor in comparative veterinary anatomy.
PROFESSIONAL AFFILIATIONS
American Board of Toxicology (Diplomate)
American College of Veterinary Pathologists (Diplomate)
American Society for Investigative Pathology
American Veterinary Medical Association
C.L. Davis, D.V.M. Foundation for the Advancement of Veterinary Pathology
Society for Developmental Biology
Society for Neuroscience
Society of Toxicologic Pathologists
Society of Toxicology
Teratology Society
ADDITIONAL PROFESSIONAL ACTIVITIES
American College of Veterinary Pathologists (ACVP)
Presenter, Neuropathology Mystery Slide Seminar, 1992, 1998
Chairperson, Neuropathology Mystery Slide Seminar, 1995
Vice Chairperson, Neuropathology Specialty Group, 1995
Chairperson, Neuropathology Specialty Group, 1996
Judge, Young Investigator Award Competition, 1997, 1998
Member, Expert Panel for the Neuropathology Mystery Slide Seminar, 2006
Member, Program Committee (Chair, Neuroscience Session), 2001
Member, Development Committee, 2002 to 2007
Member, Endowment Committee, 2000 to 2004
Member, Role Delineation Task Force, 2007 to 2008
Mentor Program, 2002 to 2004
Investigational Toxicology and Pathology Interest Group (ITPIG)
Member, 1998 to present (charter participant)
Coordinator, Position Paper Solicitation, 2003 to present
Society of Toxicologic Pathologists (STP)
Chairperson, Ad Hoc Journal Committee, 2006 to 2007
Councilor, (elected position), 2006 to 2010
Liaison, Ad Hoc Communication Strategy Task Force, 2006
Member, Ad hoc Committee on Developmental Neuropathology, 2000 to 2001 and 2005 to 2006
Member, Continuing Education Committee, 2002 to 2005
Member, Education Fund Committee (elected position), 2003
Member, Fundraising Committee, 2003 to 2006
Member, Journal Committee, 2005
Representative to International Federation of Societies of Toxicologic Pathology (IFSTP) (appointed position), 2007 to 2009
Grant Participation
Ad hoc reviewer, U.S. Department of Agriculture (1992 to 1996)
Ad hoc reviewer, Ohio Cancer Research Foundation (1999)
Journal Participation
Ad hoc Reviewer, Biochemical Pharmacology (2003)
Ad hoc Reviewer, Contemporary Topics in Laboratory Animal Science (since 1998)
Ad hoc Reviewer, Histology and Histopathology (2000)
Ad hoc Reviewer, ILAR Journal (2005)
Ad hoc Reviewer, Journal of the American Veterinary Medical Association (since 1989)
Ad hoc Reviewer, Laboratory Animal Science (1998)
Ad hoc Reviewer, NeuroToxicology (since 2006)
Ad hoc Reviewer, Teratology (since 1998)
Ad hoc Reviewer, Toxicologic Pathology (since 1996)
Ad hoc Reviewer, Toxicological Sciences (2001)
Ad hoc Reviewer, Veterinary Pathology (since 1991)
Book Reviewer, Veterinary Pathology (2005)
Editorial Board Member, Toxicologic Pathology (2004 to 2006)
Editorial Board Member, Veterinary Pathology (1999 to 2001)
Participation – Corporate Boards
Member, Scientific Advisory Board, Charles River Laboratories Pathology Group (2002)
Member, Board of Scientific Advisors, Pathology Experts LLC (2007)
RESEARCH INTERESTS
Developmental anatomy and pathology (mouse); neuropathology and neurotoxicology; pathology of genetically engineered animals; toxicity of biopharmaceutical agents.
ACTIVITIES RELATED TO PRODUCT DEVELOPMENT
Discovery pathology support for the following product development programs:
1. Anakinra – an interleukin-1 receptor antagonist (marketed as Kineret™ to treat immune-mediated joint disease)
2. Denosumab – a humanized antibody directed against receptor activator of nuclear factor kb ligand (RANKL), an osteoclast survival and differentiation factor (currently in Phase III clinical trials for several bone-eroding diseases)
3. Pegsunercept – a soluble pegylated tumor necrosis factor receptor (unmarketed molecule with similar mode of action as Enbrel™)
4. Romiplostin – a synthetic platelet growth factor (currently in Phase III clinical trials for idiopathic thrombocytic purpura)
PUBLICATIONS
Articles (* peer-reviewed)
*1. Bolon BN, St. Omer VEV (1988). Brain monoamine levels in suckling mice following postnatal exposure to secalonic acid D via the dam's miIk. Toxicol Lett 44: 263-272.
*2. Bolon B, Calderwood Mays MB (1988). Conjugated avidin-peroxidase as a stain for mast cell tumors. Vet Pathol 25: 523-525.
*3. Bolon B, St. Omer VEV (1989). Behavioral and developmental effects in suckling mice following maternal exposure to the mycotoxin secalonic acid D. Pharmacol Biochem Behav 34: 229-236.
*4. Bolon B, Buergelt CD, Cooley AJ (1989). Abortion in two foals associated with Nocardia infection. Vet Pathol 26: 277-278.
*5. Bolon B, Greiner EC, Calderwood Mays MB (1989). Microscopic features of Sarcocystis falcatula in skeletal muscle from a Patagonian conure. Vet Pathol 26: 282-284.
*6. Bolon B, Harvey JW, Buergelt CD, Meyer DJ, Kaplan-Stein D (1989). Megakaryocytic leukemia in a dog. Vet Clin Pathol 18: 69-72.
7. Francis-Floyd R, Bolon B, Jacobson E (1989). Clinical management and pathology associated with chronic weight loss in the discus, Symphysodon sp. Proceedings, 20th Annual Meeting of the International Association of Aquatic Animal Medicine, San Antonio, TX, May 14-18. 20:3-7.
8. Specht D, Francis-Floyd R, Bolon B, Watson C (1989). Significance of intestinal parasitism in the mortality of domesticalIy-bred and imported angel fish, Pterophyllum scalare. Proceedings, 20th Annual Meeting of the International Association of Aquatic Animal Medicine, San Antonio, TX, May 14-18. 20:56-62.
*9. St. Omer VEV, Bolon B (1990). Secalonic acid D (SAD) mycotoxin affects ontogeny of brain catecholamines and swimming behavior in suckling mice. Neurotoxicol Teratol 12: 85-90.
*10. Hawthorne TAB, Bolon B, Meyer DJ (1990). Amyloidosis in a mare. J Am Vet Med Assoc 196: 323-325.
*11. Bolon B, Calderwood Mays MB, Hall BJ (1990). Characteristics of canine melanomas and relationship of histology and DNA ploidy to their biologic behavior. Vet Pathol 27: 96-102.
*12. Altman D, Bolon B, Meyer DJ, Homer B (1990) Cytologic features of meningioma in a dog. Vet Clin Pathol 18: 98-100.
*13. Bolon B, Buergelt CD (1990). A simple field necropsy technique for examination of the equine cervical spinal cord. Equine Prac 12: 26-29.
14. Bonnefoi M, Bolon B, Davenport C, Morgan KT (1990). Neurotoxicology at CIIT. CIIT Activities 10: 1-7.
15. Francis-Floyd R, Bolon B, Keefe T, Fraser W, Reed P, Watson C (1990). A suspected new viral disease of angel fish. Proceedings, 21st Annual Meeting of the International Association of Aquatic Animal Medicine, Vancouver, British Columbia, May 13-17. 21: 33-37.
*16. Peele DB, Allison SD, Bolon B, Prah JD, Jensen KF, Morgan KT (1991). Functional deficits produced by 3-methylindole-induced olfactory mucosal damage revealed by a simple olfactory learning task. Toxicol Appl Pharmacol 107: 191-202.
*17. Bolon B, Bonnefoi M, Roberts K, Marshall M, Morgan KT (1991). Toxic interactions in the rat nose: Pollutants from soiled bedding and methyl bromide. Toxicol Pathol 19: 571-578, 1991.
*18. Bolon B, St. Omer VEV (1992). Biochemical correlates for behavioral deficits induced by secalonic acid D in developing mice. Neurosci Biobehav Rev 16: 171-175.
*19. Beale KM, Altman D, Clemmons RR, Bolon B (1992). Systemic toxicosis associated with azathioprine administration in domestic cats. Am J Vet Res 53: 1236-1240.
20. Beale KM, Bolon B (1992). Canine cutaneous lymphosarcoma: Epitheliotropic and non-epitheliotropic, a retrospective study. Proceedings of the 2nd World Congress of Veterinary Dermatology, Montreal, May 11-16.
*21. Robertson SA, Green SL, Carter SW, Bolon B, Brown MP, Shields RP (1992). Postanesthetic recumbency associated with hyperkalemic periodic paralysis in a quarter horse. J Am Vet Med Assoc 201: 1209-1212.
*22. Francis-Floyd R, Bolon B, Fraser W, Reed P (1993). Lip fibromas associated with retrovirus-like particles in angel fish. J Am Vet Med Assoc 202: 427-429.
*23. Fraser WA, Keefe TJ, Bolon B (1993). Isolation of an iridovirus from farm-raised gouramis (Trichogaster trichopterus) with fatal disease. J Vet Diag Invest 5: 250-253.
*24. Dorman DC, Dye JA, Nassise MP, Ekuta J, Bolon B, Medinsky MA (1993). Acute methanol toxicity in minipigs. Fundam Appl Toxicol 20: 341-347.
*25. Francis-Floyd R, Reed P, Bolon B, Estes J, McKinney S (1993). An epizootic of Edwardsiella tarda in largemouth bass (Micropterus salmoides). J Wildlife Dis 29: 334-336.
*26. Dorman DC, Bolon B, Morgan KT (1993). The toxic effects of formate in dissociated primary neural cell cultures. Toxicol Appl Pharmacol 122: 265-272.
*27. Bolon B, Dorman DC, Bonnefoi MS, Randall H, Morgan KT (1993). Histopathologic approaches to chemical toxicity using primary cultures of dissociated neural cells grown in chamber slides. Toxicol Pathol 21: 465-479.
*28. Bolon B, Dorman DC, Welsch F (1993). Phase-specific developmental toxicity in mice following maternal methanol inhalation. Fundam Appl Toxicol 21: 508-519.
*29. Bolon B, Welsch F, Morgan KT (1994). Methanol-induced neural tube defects in mice: Pathogenesis during neurulation. Teratology 49: 497-517.
*30. Fox LE, King RR, Calderwood Mays M, Cooley AJ, Meyer D, Bolon B (1994). Primary pulmonary osteosarcoma in a dog. J Small Anim Prac 35: 329-332.
*31. Dorman DC, Bolon B, Struve MF, LaPerle KMD, Wong BA, Elswick B, Welsch F (1995). The role of formate in methanol-induced exencephaly in CD-1 mice. Teratology 52: 30-40.
*32. Dorman DC, Wong BA, Struve MF, James RA, LaPerle KMD, Marshall M, Bolon B (1996) Development of a mouse whole-body exposure system from a directed-flow, rat nose-only system. Inhal Toxicol 8: 107-120.
*33. Bolon B, Dunn C, Goldsworthy TL (1996). Region-specific DNA synthesis in brains of F344 rats following a six-day bromodeoxyuridine infusion. Cell Prolif 29:505-511.
*34. Terry KK, Stedman DB, Bolon B, Welsch F (1997). Effect of 2-methoxyethanol on mouse neurulation. Teratology 54: 219-229.
*35. James SJ, Pogribna M, Miller BJ, Bolon B, Muskhelishvilli L (1997). Characterization of the cellular response to silicone implants in rats: Implications for foreign body carcinogenesis. Biomaterials 18: 667-675.
*36. Bucci TJ, Bolon B, Warbritton, AR, Chen JJ, Heindel JJ (1997). Influence of sampling on the reproducibility of ovarian follicle counts in mouse toxicity studies. Repro Toxicol 11: 689-696.
*37. Bolon B, Bucci TJ, Warbritton, AR, Chen JJ, Mattison DR, Heindel JJ (1997). Differential follicle counts as a screen for ovarian toxicity in mice: Results from continuous breeding bioassays for fifteen chemicals. Fundam Appl Toxicol 39: 1-10.
*38. Francis-Floyd R, Reed P, Gibbs P, Shotts E, Bolon B, Coleman W, Klinger R (1998). Isolation of Acholeplasma laidlawii from centrarchids in a central Florida lake. J Aquat Anim Health 10: 252-258.
*39. Hu MC-T, Wang Y, Qiu WR, Hill D, Ring BD, Bolon B, DeRose M, Simonet WS, Arakawa T, Danilenko DM (1998). FGF-18, a novel member of the fibroblast growth factor family that stimulates hepatic and intestinal proliferation. Mol Cell Biol 18: 6063-6074.
*40. Min H, Danilenko DM, Scully SA, Bolon B, Ring BD, Tarpley JE, DeRose M, Simonet WS (1998). FGF-10 is required for both limb and lung development and exhibits striking functional similarity to Drosophila branchless. Genes Dev 12: 3156-3161.
*41. LaBorde JB, Wall KS, Bolon B, Kumpe TS, Patton R, Zheng Q, Kodell R, Young JF (1999). Haematology and serum chemistry parameters of the pregnant rat. Lab Anim 33: 275-287.
*42. Kong Y-Y, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM (1999). Activated T cells regulate bone loss and joint destruction in arthritis through osteoprotegerin ligand. Nature 402: 304-309.
*43. Pauken CM, LaBorde JB, Bolon B (1999). Retinoic acid acts during peri-implantational development to alter axial and brain formation. Anat Embryol 200: 645-655.
*44. Bolon B (2000). Comparative and correlative neuroanatomy for the toxicologic pathologist. Toxicol Pathol 28: 6-27. [Companion paper to invited presentation.]
*45. Sasaki T, Irie-Sasaki J, Jones RG, Oliveira-dos-Santos AJ, Stanfield WL, Bolon B, Wakeham A, Itie A, Bouchard D, Kozieradzki I, Joza N, Mak TW, Ohashi PS, Suzuki A, Penninger JM (2000). Function of PI3Kg in thymocyte development, T cell activation and neutrophil migration. Science 287: 1040-1046.
*46. Genter MB, Burman DM, Dingeldein MW, Clough I, Bolon B (2000). Evolution of alachlor-induced nasal neoplasms in the Long-Evans rat. Toxicol Pathol 28: 770-781.
*47. Feige U, Hu Y-L, Gasser J, Campagnuolo G, Munyakazi L, Bolon B (2000). Anti-interleukin-1 and anti-tumor necrosis factor-a synergistically inhibit adjuvant arthritis in Lewis rats. Cell Mol Life Sci 57: 1457-1470.
*48. Bolon B, Carter C, Daris M, Morony S, Capparelli C, Hsieh A, Mao M, Kostenuik P, Dunstan CR, Lacey DL, Sheng J (2001). Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis. Mol Ther 3: 197-205. [Featured article on cover]
*49. Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y, Martin L, Louis J-C, Yan Q, Richards WG, Citron M, Vassar R (2001). Mice deficient in BACE1, the Alzheimer’s b-secretase, have normal phenotype and abolished b-amyloid generation. Nature Neurosci 4: 231-232.
*50. Backman SA, Stambolic V, Suzuki A, Haight J, Pretorius J, Tsao M-S, Shannon P, Bolon B, Ivy GO, Mak TW (2001). Targeted disruption of PTEN in mouse brain causes seizures and ataxia associated with neuronal cell size defects resembling Lhermitte-Duclos disease. Nature Genet 29: 396-403.
*51. Smith JC, Bolon B (2002). Atmospheric waste isoflurane concentrations using conventional equipment and rat anesthesia protocols. Contemp Topics Lab Anim Sci 41: 10-17. [Featured article on cover]
*52. Bolon B, Galbreath EJ (2002). Use of genetically engineered mice in drug discovery and development: Wielding Occam’s razor to prune the product portfolio. Int J Toxicol 21: 55-64. [Companion paper to invited presentation by BB]
*53. Campagnuolo G,1 Bolon B,1 Feige U (2002). Kinetics of bone protection by recombinant osteoprotegerin (OPG) therapy in Lewis rats with adjuvant arthritis. Arthritis Rheum 46: 1926-1936. [1Equal contributors]
*54. Coxon A,1 Bolon B,1 Estrada S, Kaufman S, Scully S, Rattan A, Duryea D, Hu Y-L, Rex K, Pacheco E, Zack D, Feige F (2002). Inhibition of IL-1 but not TNF inhibits neovascularization in rat models of corneal angiogenesis and adjuvant arthritis. Arthritis Rheum 46: 2604-2612. [1Equal contributors]
*55. Bolon B,1 Campagnuolo G,1 Feige U (2002). Duration of bone protection afforded by a single injection of recombinant osteoprotegerin (OPG) in male Lewis rats with adjuvant-induced arthritis. Cell Mol Life Sci 59: 1569-1576. [1Equal contributors]
*56. Bolon B, Shalhoub V, Kostenuik PJ, Campagnuolo G, Morony S, Boyle WJ, Zack D, Feige U (2002). Osteoprotegerin (OPG): an endogenous anti-osteoclast factor for protecting bone in rheumatoid arthritis. Arthritis Rheum 46: 3121-3135. [Invited review]
*57. Genter MB, Burman D, Bolon B (2002). Progression of alachlor-induced olfactory mucosal tumors in rats. Int J Exp Pathol 83: 303-307.
*58. Campagnuolo G,1 Bolon B,1 Zhu L, Duryea D, Feige U, Zack D (2003). IL-1b and TNF-a produce divergent acute inflammatory and skeletal lesions in the knees of Lewis rats. Ann NY Acad Sci 987: 295-298. [1Equal contributors]
*59. Smith JC, Bolon B (2003). Comparison of three commercially available activated charcoal canisters for passive scavenging of waste isoflurane during conventional rodent anesthesia. Contemp Topics Lab Anim Sci 42: 10-15. [Featured article on cover]
*60. Luo Y, Bolon B, D’Amore MA, Fitzpatrick D, Liu H, Zhang J, Yan Q, Vassar R, Citron M (2003). BACE1 (b-secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time. Neurobiol Dis 14: 81-88.
*61. Schett G, Redlich K, Hayer S, Zwerina J, Bolon B, Dunstan C, Görtz B, Schulz A, Bergmeister H, Kollias G, Steiner G, Smolen JS (2003). Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Rheum 48: 2042-2051.
*62. Discenza MT, He SJ, Lee TH, Chu LL, Bolon B, Goodyer P, Eccles M, Pelletier M (2003). WT1 is a modifier of the Pax2 mutant phenotype: cooperation and interaction between WT1 and Pax2. Oncogene 22: 8145-8155.
*63. Bolon B, Morony S, Cheng Y, Hu Y-L, Feige U (2004). Osteoclast numbers in Lewis rats with adjuvant-induced arthritis: Identification of preferred sites and parameters for rapid quantitative analysis. Vet Pathol 41: 30-36.
*64. Smith JC, Corbin TJ, McCabe JG, Bolon B (2004). Isoflurane with morphine is a favorable anesthetic regimen for embryo transfer in production of transgenic rats. Lab Anim 38: 38-43.
*65. Nakayama N, Han CE, Cam L, Lee JI, Pretorius J, Fisher S, Rosenfeld R, Scully S, Nishinakamura R, Duryea D, Van G, Bolon B, Yokota T, Zhang K (2004). A novel chordin-like BMP inhibitor, CHL2, expressed preferentially in chondrocytes of developing cartilage and osteoarthritic joint cartilage. Development 131: 229-240.
*66. Kostenuik P,1 Bolon B,1 Morony S, Daris M, Geng Z, Carter C, Sheng J (2004). Gene therapy with human recombinant osteoprotegerin (OPG) reverses established osteopenia in ovariectomized mice. Bone 34:656-664 [1Equal contributors]
*67. Bolon B, Jing S, Asuncion F, Scully S, Pisegna M, Van G, Hu Z, Yu YB, Min H, Wild K, Rosenfeld RD, Tarpley J, Carnahan J, Duryea D, Hill D, Kaufman S, Yan X-Q, Juan T, Christensen K, McCabe J, Simonet WS (2004). The candidate neuroprotective agent artemin induces autonomic neural dysplasia without preventing peripheral nerve dysfunction. Toxicol Pathol 32: 275-294.
*68. Bolon B, Campagnuolo G, Zhu L, Duryea D, Zack D, Feige U (2004). Interleukin-1b and tumor necrosis factor-a produce distinct, time-dependent patterns of acute arthritis in the rat knee. Vet Pathol 41: 235-243.
*69. Smith JC, Bolon B (2004). Endotracheal tubes vs. laryngeal mask airways in rabbit inhalation anesthesia: ease of use and waste gas emissions. Contemp Topics Lab Anim Sci 45: 22-25.
*70. Bolon B (2004). Genetically engineered animals in drug discovery and development: A maturing resource for toxicologic research. Basic Clin Pharmacol Toxicol 95: 154-161. [Invited review]
71. Bolon B (2004). Immune-mediated arthritis: Molecular mechanisms and comparative pathology. Proceedings of the 55th Annual Meeting of the American College of Veterinary Pathologists, Orlando, FL, November 13-17, pp. 270-273. [Brief to accompany invited presentation]
*72. Schett G, Middleton S, Bolon B, Stolina M, Brown H, Zhu L, Pretorius J, Zack DJ, Kostenuik P, Feige U (2005). Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models. Arthritis Rheum 52: 1604-1611
*73. Schett G, Stolina M, Bolon B, Middleton S, Adlam M, Brown H, Zhu L, Feige U, Zack DJ (2005). Analysis of the kinetics of osteoclastogenesis in arthritic rats. Arthritis Rheum 52: 3192-3201.
*74. Genter MB, Warner BM, Krell H-W, Bolon B (2005). Reduction of alachlor-Induced olfactory mucosal neoplasms by the matrix metalloproteinase inhibitor Ro-28-2653. Toxicol Pathol 33:593-599.
*75. Stolina M, Adamu S, Ominsky M, Dwyer D, Asuncion F, Geng Z, Middleton S, Brown H, Pretorius J, Schett G, Bolon B, Feige U, Zack D, Kostenuik PJ (2005). RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. J Bone Min Res 20: 1756-1765.
*76. Bolon B (2006). Internet resources for phenotyping engineered rodents. ILAR J 47: 163-171. [Invited review]
*77. Smith JC, Bolon B (2006). Comparative isoflurane leakage from conventional facemasks on a non-rebreathing rodent anesthesia system. Lab Anim 40: 200-209.
*78. Bolon B, Garman R, Jensen K, Krinke G, Stuart B (2006). A ‘best practices’ approach to neuropathologic assessment in developmental neurotoxicity testing – for today. Toxicol Pathol 34: 296-313. [STP position paper]
*79. Li J, Sarosi I, Cattley RC, Pretorious J, Asuncion F, Grisanti M, Morony S, Adamu S, Geng Z, Qiu W, Kostenuik P, Lacey DL, Simonet WS, Bolon B, Qian X, Shalhoub V, Ominsky MS, Zhu Ke H, Li X, Richards, WG (2006). Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 39: 754-766.
*80 Holst CR, Bou-Reslan H, Gore BB, Wong K, Grant D, Chalasani S, Carano RA, Frantz G, Tessier-Lavigne M, Bolon B, French DM, Ashkenazi A. Secreted sulfatases Sulf1 and Sulf2 have overlapping yet essential roles in mouse neonatal survival. PLoS ONE 2: e575.
*81. Stolina M, Dwyer D, Ominsky MS, Corbin T, Van G, Bolon B, Sarosi I, McCabe J, Zack DJ, Kostenuik P (2007). Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses. J Immunol 179: 7497-7505.
*82 Bolon B. Whole mount enzyme histochemistry as a rapid screen at necropsy for expression of ß-galactosidase (LacZ)-bearing transgenes: Considerations for separating specific LacZ activity from non-specific (endogenous) galactosidase activity. Toxicol Pathol (in press).
Book Chapters
1. Bolon B (1992). The special physiology and anatomy of goldfish, carp and koi. In: Fish Medicine (Stoskopf M, ed.). W.B. Saunders, Philadelphia, pp. 447-450.
2. Bolon B (1992). The special physiology and anatomy of freshwater tropical fish. In: Fish Medicine (Stoskopf M, ed.). W.B. Saunders, Philadelphia, pp. 540-543.
3. Bolon B, Stoskopf MK (1995). Fish models in biomedical research: Basic principles for care and use. In: The Experimental Animal in Biomedical Research, Vol. II (Rollin BE, Kessel ML, eds.). CRC Press, Boca Raton, FL, pp. 15-29.
4. Bolon B, Hagstrom T (1997). Diagnostic procedures: Cytology. In: The Biology, Husbandry, and Health Care of Reptiles, Vol. III (Ackerman L, ed.). TFH Publications Inc., Neptune, NJ, pp. 876-885.
5. Bolon B (1997). Necropsy (post mortem examination). In: The Biology, Husbandry, and Health Care of Reptiles, Vol. III (Ackerman L, ed.). TFH Publications Inc., Neptune, NJ, pp. 858-870.
6. Bolon B, Galbreath EJ, Sargent L, Weiss J (2000). Genetic engineering and molecular technology. In: The Laboratory Rat (Krinke G, ed.). Academic Press, London, pp. 603-634.
7. Dorman DC, Brenneman K, Bolon B (2002). Nervous System. In: Handbook of Toxicologic Pathology, 2nd ed. (Haschek-Hock W, Rousseaux CG, Wallig MA, eds.). Academic Press, San Diego, pp. 509-537.
8. Bolon B, Shalhoub V, Kostenuik PJ, Zack D, Feige U (2004). Receptor activator of nuclear factor kB ligand (RANKL) and osteoprotegerin (OPG): the yin and yang of joint integrity. In: Cytokines and Joint Injury (van den Berg WB, Miossec P, eds.). Birkhäuser Verlag, Basel, pp. 221-267.
9. Bussiere JL, Bolon B (2004). Knockout, genetic. In: Encyclopedic Reference of Immunotoxicology (Vohr H-W, ed.). Springer Verlag, Berlin, pp. 368-371.
10. Bolon B (2004). Lymphocyte. In: Encyclopedic Reference of Immunotoxicology (Vohr H-W, ed.). Springer Verlag, Berlin, pp. 408-411.
11. Bolon B (2007). Genetically engineered animals. In: Comprehensive Medicinal Chemistry, 2nd ed. (Taylor JB, Triggle DJ, series eds.), Vol. 3: Drug Discovery Technologies. (Kubinyi H, volume ed.). Elsevier, Oxford, pp. 151-170.
Edited Books
1. Bolon B and Butt M. Neuropathology for Toxicologists and Pathologists. Wiley, Philadelphia (in preparation).
2. Bolon B. Pathology of the Developing Mouse: A Systematic Approach. CRC Press, Boca Raton, FL (in preparation).
Invited Presentations
1. The developmental neurotoxicity of methanol (1993). Invited research seminar, the Secretary's Scientific Advisory Board on Toxic Air Pollutants, North Carolina Dept. of Environment, Health and Natural Resources, Raleigh, NC, August 16.
2. Immunohistochemistry as the pathologist's contribution to risk assessment (1995). Thirteenth Annual Meeting, South Central Flow Cytometry Association, Little Rock, AR, May 5.
3. Weird science: The pathologist’s contribution to genetic engineering (1997). International Life Sciences Institute 2nd Histopathology Seminar on the Nervous System of Laboratory Animals, Hannover Medical School, Germany, September 3-5.
4. The virtual brain: Mechanistic pathology in risk assessment (1997). International Life Sciences Institute 2nd Histopathology Seminar on the Nervous System of Laboratory Animals, Hannover Medical School, Germany, September 3-5.
5. Strategies for high throughput phenotypic analysis of genetically engineered mice (1999). Invited research seminar, Careers in Industrial Research Seminar, Chemical Industry Institute of Toxicology, Research Triangle Park, NC, February 22.
6. Strategies for high throughput phenotypic analysis of genetically engineered mice (1999). Research Seminar, College of Veterinary Medicine, University of Missouri, Columbia, MO, March 12.
7. Applied embryology of the mouse (1999). 17th West Coast Veterinary Pathology Conference, Thousand Oaks, CA, June 4-5.
8. Comparative and correlative neuroanatomy for the toxicologic pathologist (1999). Society of Toxicologic Pathologists Symposium on “Toxicologic Pathology of the Nervous System”, Washington, D.C., June 14-17.
9. Designer mice in drug development: Using Occam’s razor to prune the product patch (2000). American College of Toxicology, San Diego, CA, November 12-15.
10. Facing your worst nightmare: Practical embryology practices for use in genetically engineered mice (2001). Research seminar, College of Veterinary Medicine, Washington State University, Pullman, WA, April 19.
11. Phenotypic analysis of genetically engineered mice: A pathologist’s perspective (2001). Research seminar, College of Veterinary Medicine, Washington State University, Pullman, WA, April 20.
12. Osteoprotegerin (OPG) gene therapy in animal models of osteoarticular disease (2001). Proceedings, 2nd International Meeting on Innovative Rheumatology, Montpellier, France, May 17-18
13. Osteoprotegerin-ligand inhibition to control osteoclast activity in inflammatory arthritis (2002). Proceedings, 6th International Symposium on the Immunotherapy of the Rheumatic Diseases, Limassol, Cyprus, May 15-19.
14. Use of genetically engineered mice in drug discovery and development (2003). Society of Toxicology, Salt Lake City, UT, March 9-13.
15. Designer mice in drug discovery: Using genetically engineered mice to prune the product portfolio (2003). Society of Toxicology, Salt Lake City, UT, March 9-13.
16. Applied mouse embryology (2003). 2nd Annual Short Course on the Pathobiology of the Laboratory Mouse, The Jackson Laboratory, Bar Harbor, MN, July 6-13.
17. Use of genetically engineered mice in drug discovery and development (2004). West Coast Veterinary Pathology Conference, C.L. Davis DVM Foundation, Asilomar, CA, May 13-14.
18. Neurodevelopment: Issues and assessment (2004). 2nd RTP Rodent Pathology Course (Pathology of the Nervous System), National Institute of Environmental Health Sciences, Research Triangle Park, NC, September 12-14.
19. Immune-mediated arthritis: Molecular mechanisms and comparative pathology (2004). 55th Annual Meeting of the American College of Veterinary Pathology, Orlando, FL, November 13-17.
20. Pathology of the developing mouse: Practices and pitfalls (2005). Research seminar, Genentech, South San Francisco, CA, April 1.
21. Neurological phenotyping of genetically engineered mice (2005). 2nd European Course on the Pathology and Embryology of Genetically Engineered Mice (EuroGEMs), Nantes, France, May 9-13.
22. Utility of genetically engineered mice in pharmaceutical development (2005). 2nd European Course on the Pathology and Embryology of Genetically Engineered Mice (EuroGEMs), Nantes, France, May 9-13.
23. Immune-mediated arthritis: Molecular mechanisms and comparative pathology (2005). Invited research seminar, ESBATech AG, Zurich-Schlieren, Switzerland, May 17.
24. Mining malformed minds: Neurological phenotyping of engineered mice (2005). Invited research seminar, College of Veterinary Medicine, University of Missouri, Columbia, MO, October 24.
25. Humpty Dumpty's legacy: developmental pathology of engineered mice (2005). Invited research seminar, College of Veterinary Medicine, University of Missouri, Columbia, MO, October 25.
26. What's wrong with my mouse? Phenotyping schemes for engineered mice (2005). Invited research seminar, Lilly, Indianapolis, IN, October 31.
27. Fundamental principles of neuropathologic evaluation in assessing neurotoxic risk (2005). U.S. Food and Drug Administration (FDA), Silver Spring, MD, November 14.
28. Current practices and challenges in developmental neuropathology (2005). Seminar on Advanced Pathologic Techniques: Current Issues in Neuropathology (a satellite meeting to the annual ACVP meeting), Boston, MA, December 2.
29. Oh, my aching head: Toxicant-Induced neuropathology in the central nervous system (2006). Invited continuing education seminar, Society of Toxicology, San Diego, CA, March 5-9.
30. Blasted brains and other neural nightmares: Neuropathology for the non-neuropathologist (2006). West Coast Veterinary Pathology Conference, C.L. Davis DVM Foundation, Asilomar, CA, April 7-8.
31. The art of arthritis: comparative pathology of immune-mediated joint disease (2006). University of Kansas Medical Center, Pathology Grand Rounds, Kansas City, MO, May 1.
32. Comparative pathology of immune-mediated joint disease (2006). Amgen, Inc., Thousand Oaks, CA, May 6.
33. Developmental pathology of engineered mice (2007). Keynote speaker at the 2nd Annual Phenotyping Symposium, Johns Hopkins Medical Institute, Johns Hopkins University, Baltimore, MD, March 20.
34. Immune-mediated arthritis: comparative pathology, mechanisms and methods (2007). Roche, Palo Alto, CA, July 30
35. Phenotypic analysis of rodent placenta (2007). International Federation of Placenta Associations, Kingston, ON, Canada, August 18-22.
36. Hitting the right fan: selecting a journal for your science fiction (2007). American College of Veterinary Pathologists Symposium on “Dancing with Journals,” Savannah, GA, November 10-14.
